ライフサイエンスコーパス: Sjogren's syndrome

1 pression, cognitive disorders, arthritis and Sjogren's syndrome).

2 (diabetes, thyroiditis); and rheumatologic (Sjogren's syndrome).

3 e diseases (lupus, rheumatoid arthritis, and Sjogren's syndrome).

4 ab in patients with rheumatoid arthritis and Sjogren's syndrome.

5 desiccating stress (DS) model that resembles Sjogren's syndrome.

6 ant CD4(+) infiltration in the LG, mimicking Sjogren's syndrome.

7 iduals with systemic lupus erythematosus and Sjogren's Syndrome.

8 ormal T-cell development and activation, and Sjogren's Syndrome.

9 antibodies in the serum resemble autoimmune Sjogren's syndrome.

10 epletion in systemic lupus erythematosus and Sjogren's syndrome.

11 and aberrant histopathology associated with Sjogren's syndrome.

12 ent from inflammation in the pathogenesis of Sjogren's syndrome.

13 chizophrenia greatly reduce risk for SLE and Sjogren's syndrome.

14 mandibular gland (SMG), a critical target of Sjogren's syndrome.

15 no such studies published or in progress for Sjogren's syndrome.

16 immunologic and nonimmunologic mechanisms in Sjogren's syndrome.

17 ry process in salivary glands that resembles Sjogren's syndrome.

18 systemic sclerosis, rheumatoid arthritis, or Sjogren's syndrome.

19 esembles the disease manifestations of human Sjogren's syndrome.

20 tients with systemic lupus erythematosus and Sjogren's syndrome.

21 imilar to that found in humans with lupus or Sjogren's syndrome.

22 en's syndrome, develop an illness similar to Sjogren's syndrome.

23 function that is highly reminiscent of human Sjogren's syndrome.

24 mation and are models for the human disorder Sjogren's syndrome.

25 rimal gland damage in these murine models of Sjogren's syndrome.

26 om infection or autoimmune disorders such as Sjogren's syndrome.

27 lands, similar to that in the human disorder Sjogren's syndrome.

28 e antibodies was less in patients with RA or Sjogren's syndrome.

29 ematosus and 125 white patients with primary Sjogren's syndrome.

30 hocytes in the initiation and propagation of Sjogren's syndrome.

31 ation and are a model for the human disorder Sjogren's syndrome.

32 d neck cancer or autoimmune diseases such as Sjogren's syndrome.

33 a reactive infiltrate, often associated with Sjogren's syndrome.

34 n spontaneously develops that is a model for Sjogren's syndrome.

35 oimmune response such as that encountered in Sjogren's syndrome.

36 nction of lacrimal glands in mouse models of Sjogren's syndrome.

37 inflammation, and serve as a model for human Sjogren's syndrome.

38 ding insulin-dependent diabetes mellitus and Sjogren's syndrome.

39 hoid infiltrate that occurs in patients with Sjogren's syndrome.

40 or autoimmune insulin-dependent diabetes and Sjogren's syndrome.

41 nection with the autoimmune exocrinopathy of Sjogren's syndrome.

42 provide insight into the immunopathology of Sjogren's syndrome.

43 not satisfy the criteria for a diagnosis of Sjogren's syndrome.

44 milar to those seen in the pseudolymphoma of Sjogren's syndrome.

45 The other was from a patient with secondary Sjogren's syndrome.

46 europathy and the neuropathy associated with Sjogren's syndrome.

47 ell neoplasms that are often associated with Sjogren's syndrome.

48 /lpr mice are a model for the human disorder Sjogren's syndrome.

49 esions and are a model for the human disease Sjogren's syndrome.

50 and IgG-positive cells, resemble lesions of Sjogren's syndrome.

51 ip biopsy findings that met the criteria for Sjogren's syndrome.

52 ce of complete heart block in a patient with Sjogren's syndrome.

53 upus erythematosus, rheumatoid arthritis and Sjogren's syndrome.

54 BCCAO may be present in patients with Sjogren's syndrome.

55 acute visual loss is found in a patient with Sjogren's syndrome.

56 he systemic symptoms associated with primary Sjogren's syndrome.

57 associated with the autoimmune exocrinopathy Sjogren's syndrome.

58 60 in systemic lupus erythematosus (SLE) and Sjogren's syndrome.

59 targeted in systemic lupus erythematosus and Sjogren's syndrome.

60 nd diseases such as head and neck cancer and Sjogren's syndrome.

61 s, polymyositis/dermatomyositis, and primary Sjogren's syndrome.

62 tients with systemic lupus erythematosus and Sjogren's syndrome.

63 linked to development of type 1 diabetes and Sjogren's syndrome.

64 ses such as systemic lupus erythematosus and Sjogren's syndrome.

65 ce of an infectious environmental trigger in Sjogren's syndrome.

66 lved in both innate and adaptive immunity in Sjogren's syndrome.

67 esults of a large-scale association study of Sjogren's syndrome.

68 in turn may predispose to the development of Sjogren's syndrome.

69 y for systemic lupus erythematosus (SLE) and Sjogren's syndrome.

70 cent confidence interval, 0.59 to 1.73]; and Sjogren's syndrome, 1.42 [95 percent confidence interval

71 ntly more patients presenting with secondary Sjogren's syndrome (15.7%).

72 ported most frequently by PBC cases included Sjogren's syndrome (17.4%) and Raynaud's syndrome (12.5%

73 ot the clinical profile; 7 had lupus, 14 had Sjogren's syndrome, 7 had both, and 23 were asymptomatic

74 eart block associated with anti-SSA/Ro (anti-Sjogren's Syndrome A/Ro) antibodies.

75 athology and aberrant function mimic that of Sjogren's syndrome, a human autoimmune disease character

76 In patients with primary Sjogren's syndrome, a single treatment course of rituxim

77 eases systemic lupus erythematosus (SLE) and Sjogren's syndrome affect nine times more women than men

78 sclerosis affects 49,000 adults, and primary Sjogren's syndrome affects from 0.4 million to 3.1 milli

79 Sjogren's syndrome alters the protein profile and brings

80 sk for SLE and 16-fold variation in risk for Sjogren's syndrome among individuals with common C4 geno

81 ntal factors that control the development of Sjogren's syndrome, an autoimmune disease mainly involvi

82 dvancing toward nonbiopsy-based diagnosis of Sjogren's Syndrome, an autoimmune disease.

83 In patients with Sjogren's syndrome and a secretory-defect distal renal t

84 nt discoveries from studies in patients with Sjogren's syndrome and animal models suggest a complex i

85 Both Sjogren's syndrome and common variable immunodeficiency

86 Dry mouth is a primary symptom of Sjogren's syndrome and is a side effect of many drug tre

87 en deficiency may promote the progression of Sjogren's syndrome and its associated lacrimal gland inf

88 eles in men, women's greater risk of SLE and Sjogren's syndrome and men's greater vulnerability to sc

89 kappaB signaling as a therapeutic target for Sjogren's Syndrome and other autoimmune diseases.

90 e hormone, may be useful in the treatment of Sjogren's syndrome and other human autoimmune diseases.

91 ntibody-mediated autoimmune diseases such as Sjogren's syndrome and rheumatoid arthritis.

92 s are becoming clearer in conditions such as Sjogren's syndrome and scleroderma.

93 the lymphomas seen in elderly patients with Sjogren's syndrome and SLE.

94 d is an autoantigen present in patients with Sjogren's syndrome and systemic lupus erythematosus.

95 f the statistical model appear to operate in Sjogren's syndrome and systemic sclerosis whereas only t

96 oral dryness is experienced by sufferers of Sjogren's syndrome and those treated with irradiation fo

97 risk for SLE, 31-fold variation in risk for Sjogren's syndrome, and 1.7-fold variation in schizophre

98 e diseases, including lupus, scleroderma and Sjogren's syndrome, and had a prominent transcriptomic o

99 develop autoantibodies, sialadenitis, as in Sjogren's syndrome, and immune complex-mediated nephriti

100 caused by medications, chronic diseases like Sjogren's syndrome, and medical treatments, such as radi

101 mplementemic urticarial vasculitis syndrome, Sjogren's syndrome, and mixed cryoglobulinemia.

102 ltiple sclerosis (MS), rheumatoid arthritis, Sjogren's syndrome, and myasthenia gravis.

103 mechanistic insight into the development of Sjogren's Syndrome, and suggest the potential of NF-kapp

104 c inflammatory demyelinating polyneuropathy, Sjogren's syndrome, and systemic lupus erythematosus tha

105 Currently, no effective treatments exist for Sjogren's syndrome, and there is a limited understanding

106 athomechanisms and involvement of viruses in Sjogren's syndrome, and to highlight the areas for futur

107 cell arteritis, ankylosing spondylitis, and Sjogren's syndrome, and to provide an overall estimate o

108 Currently, there is no cure for Sjogren's syndrome, and treatment is mainly palliative.

109 the lacrimal gland, and the presence of anti-Sjogren's syndrome antigen A and anti-Sjogren's syndrome

110 activated by the La autoantigen, also called Sjogren's syndrome antigen B (SSB).

111 the human Ago2 minimal RISC system to purify Sjogren's syndrome antigen B (SSB)/autoantigen La as an

112 Human La antigen (Sjogren's syndrome antigen B [SSB]) is an abundant multi

113 f anti-Sjogren's syndrome antigen A and anti-Sjogren's syndrome antigen B antibodies in the serum res

114 La antigen (Sjogren's syndrome antigen B) is a phosphoprotein associ

115 The most common symptoms of Sjogren's syndrome are extreme tiredness, along with dry

116 tients with systemic lupus erythematosus and Sjogren's syndrome are influenced by the HLA class II ge

117 Autoimmune myositis, vasculitis and primary Sjogren's syndrome are rare diseases in which these ther

118 tricted autoantigens (e.g., M3R) targeted in Sjogren's syndrome are specifically cleaved by granzyme

119 eratitis or KCS, a condition that is seen in Sjogren's syndrome, are dependent on NF-kappaB, but are

120 ics of systemic lupus erythematosus (SLE) or Sjogren's syndrome as the era of genome-wide association

121 ate of saliva and tear flow in patients with Sjogren's syndrome, as well as improving subjective symp

122 ong similarity to the 52-kD Ro/SSA lupus and Sjogren's syndrome auto-antigen and the RET finger prote

123 In autoimmune exocrinopathy (Sjogren's syndrome), autoantibodies to the intracellular

124 age and the generation of novel fragments of Sjogren's syndrome autoantigens in this form of apoptosi

125 A human La/Sjogren's syndrome-B (hLa)-specific TCR/hLa neo-self-Ag

126 seen in the salivary glands of patients with Sjogren's syndrome, but it is not known whether the micr

127 to implicate viral infection in the cause of Sjogren's syndrome, but there are no definitive studies

128 us to develop a therapy in the treatment of Sjogren's syndrome by increasing the water permeability

129 ry glands from pathologic conditions such as Sjogren's syndrome can result in glandular destruction a

130 otein 3 (LAMP3/CD208/DC-LAMP) in a subset of Sjogren's syndrome cases.

131 (95% CI: 0.8, 7.8) for RA, scleroderma, and Sjogren's syndrome combined and 1.9 (95% CI: 0.6, 6.2) f

132 on was increased in PBMCs from patients with Sjogren's syndrome compared with healthy controls.

133 Dry eye disorders, including Sjogren's syndrome, constitute a common problem in the a

134 The criteria for diagnosis of primary Sjogren's syndrome continue to be controversial, leading

135 Hashimoto's thyroiditis and Graves' disease, Sjogren's syndrome, dermatitis herpetiformis, recurrent

136 017), the findings for rheumatoid arthritis, Sjogren's syndrome, dermatomyositis or polymyositis, or

137 ch is a common target of the autoimmunity of Sjogren's syndrome, develop an illness similar to Sjogre

138 or autoimmune disorders, and in the case of Sjogren's syndrome directly in saliva, requiring about a

139 dose-ranging cohort 1, patients with a EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) score

140 hemolytic anemia, interstitial cystitis, and Sjogren's syndrome had higher prevalence rates among pat

141 mothers with systemic lupus erythematosus or Sjogren's syndrome, had a second child with cardiac NL (

142 (MHC) locus, an association that in SLE and Sjogren's syndrome has long been thought to arise from a

143 ogenesis of systemic lupus erythematosus and Sjogren's syndrome has provided a strong rationale to sp

144 Up to 90% of individuals with Sjogren's syndrome have antibodies targeting the Ro 60 a

145 ing excellent oral hygiene, individuals with Sjogren's syndrome have elevated levels of dental caries

146 Recent studies on each of these steps in Sjogren's syndrome have suggested their role in pathogen

147 es), including systemic lupus erythematosus, Sjogren's syndrome, hemolytic anemia, thrombocytopenia,

148 syndrome in 4, systemic lupus erythematosus/Sjogren's syndrome in 1, and undifferentiated autoimmune

149 MCGN was related to primary Sjogren's syndrome in 22.5% of patients and to lymphopro

150 s had manifestations of autoimmune diseases (Sjogren's syndrome in 4, systemic lupus erythematosus/Sj

151 immunosuppressive medications and secondary Sjogren's syndrome in the development of lymphoma in SLE

152 nitive studies are still lacking for primary Sjogren's syndrome, incidental reports indicating potent

153 ncluding systemic lupus erythematosus (SLE), Sjogren's syndrome, inflammatory bowel disease and multi

154 Sjogren's syndrome is a chronic autoimmune disorder of t

155 Sjogren's syndrome is a common autoimmune disease (affec

156 Sjogren's syndrome is a common autoimmune rheumatic dise

157 Sjogren's syndrome is a poorly understood autoimmune inf

158 Sjogren's syndrome is an autoimmune disease characterize

159 t with chronic rheumatoid arthritis (RA) and Sjogren's syndrome is described.

160 Genetic evaluation of Sjogren's syndrome is limited to small studies that have

161 Natural aging, regardless of Sjogren's syndrome, is also another factor that brings a

162 of SLE is advancing rapidly, whereas that of Sjogren's syndrome lags behind considerably.

163 oes not cause lacrimal gland inflammation, a Sjogren's syndrome-like pathology in lacrimal tissue, or

164 lacrimal tissue, leading to inflammation, a Sjogren's syndrome-like pathology, and aqueous tear defi

165 on also increases incidence of a spontaneous Sjogren's syndrome-like pathology, characterized by lymp

166 hepatitis C virus infection clearly causes a Sjogren's-syndrome-like illness.

167 crimal gland lesions in this murine model of Sjogren's syndrome may contribute to the predominantly T

168 nts with rheumatoid arthritis (RA) (n = 80), Sjogren's syndrome (n = 30), polymyositis and dermatomyo

169 nkylosing spondylitis (AS) (n = 10), primary Sjogren's syndrome (n = 6), juvenile chronic arthritis (

170 NA-1, the Caenorhabditis elegans ortholog of Sjogren's Syndrome Nuclear Antigen 1, is a constituent o

171 Sjogren's Syndrome nuclear autoantigen 1 (SSNA1 or NA14)

172 NHL was associated with Sjogren's syndrome (odds ratio (OR) = 13, 95% confidence

173 other autoimmune diseases, including primary Sjogren's syndrome (OR = 2.45 in Chinese, OR = 2.35 in E

174 crinopathy can be encountered alone (primary Sjogren's syndrome) or in the presence of another autoim

175 difference in the prevalence of thyroiditis, Sjogren's syndrome, or Hodgkin's or NHL.

176 h autoimmune disease (P = 0.005), especially Sjogren's syndrome (P = 0.001) and thyroid disease (P =

177 ex (ESSDAI) score of 5 or higher and a EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) score

178 Kingdom, HERV-K113 was found in 15.6% of 96 Sjogren's syndrome patients (p < 0.01) and 11.9% of 109

179 or salivary gland biopsies from controls and Sjogren's syndrome patients identified increased express

180 Accordingly, labial biopsies from primary Sjogren's syndrome patients showed reduced Gal1 expressi

181 Among Sjogren's syndrome patients who fulfill the European cri

182 rom Sjogren's syndrome patients, 37 from non-Sjogren's syndrome patients), 2 of which were positive.

183 Ninety-two samples were examined (55 from Sjogren's syndrome patients, 37 from non-Sjogren's syndr

184 ents from parental NOD mice or human primary Sjogren's syndrome patients, but not serum IgG from heal

185 pofunction and dry mouth symptoms in primary Sjogren's syndrome patients.

186 s taking place within the salivary glands of Sjogren's syndrome patients.

187 s of labial salivary gland biopsies from two Sjogren's syndrome patients.

188 on injury, Salmonella infection, uveitis and Sjogren's syndrome, PEPITEM reduced T cell recruitment i

189 2 diabetes, B-cell lymphoma, lichen planus, Sjogren's syndrome, porphyria cutanea tarda, rheumatoid-

190 ncluding systemic lupus erythematosus (SLE), Sjogren's syndrome, primary biliary cirrhosis, and activ

191 stemic lupus erythematosus (SLE) and primary Sjogren's syndrome (pSS) are typically characterized by

192 Primary Sjogren's syndrome (pSS) confers increased risk for non-

193 This cytokine is implicated in primary Sjogren's syndrome (pSS) immunopathology because of the

194 Primary Sjogren's syndrome (pSS) is a chronic autoimmune disease

195 Primary Sjogren's syndrome (pSS) is a chronic autoimmune disease

196 Primary Sjogren's syndrome (pSS) is a complex autoimmune disease

197 Primary Sjogren's syndrome (pSS) is a complex autoimmune disease

198 Primary Sjogren's Syndrome (PSS) is a highly prevalent autoimmun

199 Primary Sjogren's syndrome (pSS) is a prototype of chronic autoi

200 Primary Sjogren's Syndrome (pSS) is an autoimmune disease involv

201 repertoire in the parotid glands of primary Sjogren's syndrome (pSS) patients before and after ritux

202 In primary Sjogren's syndrome (pSS) the exocrine glands become infi

203 The association of primary Sjogren's syndrome (pSS) with Major Histocompatibility C

204 veral autoimmune diseases, including primary Sjogren's syndrome (pSS), are associated with an increas

205 still no disease-modifying drug for primary Sjogren's syndrome (pSS).

206 n which a total of 497 subjects with primary Sjogren's syndrome received 150 international units of h

207 nce interval (CI): 1.35 - 1.51, p < 0.0001], Sjogren's syndrome-related (aHR: 1.67, 95% CI:1.46 - 1.9

208 .67, 95% CI:1.46 - 1.90, p < 0.0001) and non-Sjogren's syndrome-related subtypes (aHR: 1.38, 95% CI:

209 cleroderma, systemic lupus erythematosus, or Sjogren's syndrome (relative risk = 2.0, 95% confidence

210 c NHL subtypes were strongly associated with Sjogren's syndrome: salivary gland (OR = 290, 95% CI: 33

211 received an alternative diagnosis, including Sjogren's syndrome, sensory chronic inflammatory demyeli

212 e and safety of minor salivary gland biopsy, Sjogren's syndrome serves as a prototype model to study

213 onjunctivitis sicca (KCS), autoimmunity, and Sjogren's syndrome (SjS) have yet to be defined.

214 Sjogren's syndrome (SjS) is a chronic autoimmune disease

215 The development of Sjogren's syndrome (SjS) is a dynamic and temporal proce

216 Sjogren's syndrome (SjS) is a human autoimmune disease c

217 detection of patient serum autoantibodies in Sjogren's Syndrome (SjS), a chronic autoimmune disease a

218 The role of complement in the etiology of Sjogren's syndrome (SjS), a human autoimmune disease man

219 s that plays a direct role in development of Sjogren's syndrome (SjS), a systemic autoimmune disease

220 vely, many features of primary and secondary Sjogren's syndrome (SjS), an autoimmune disease affectin

221 s reacting against salivary gland tissues in Sjogren's syndrome (SjS), an autoimmune disease targetin

222 M3R is often the target of autoantibodies in Sjogren's syndrome (SjS), chemical agonists for M3R are

223 al glands (LGs) of male NOD mice, a model of Sjogren's syndrome (SjS), exhibit immune cell infiltrati

224 Sjogren's syndrome-specific autoantibodies (SSA/Ro and S

225 vary gland epithelial cells in patients with Sjogren's syndrome (SS) and in NOD and NODscid mice expr

226 salivary glands of control subjects without Sjogren's syndrome (SS) and patients with SS who had low

227 E) and heart block, as well as patients with Sjogren's syndrome (SS) and systemic lupus erythematosus

228 -associated meibomian gland disease (MGD) or Sjogren's syndrome (SS) aqueous tear deficiency (ATD).

229 ubgroups with meibomian gland disease (MGD), Sjogren's syndrome (SS) aqueous tear deficiency, or neur

230 cular surface in autoimmune diseases such as Sjogren's syndrome (SS) causes an aqueous-deficient dry

231 Salivary glands in patients with Sjogren's syndrome (SS) develop ectopic lymphoid structu

232 44-year-old woman with a 12-year history of Sjogren's syndrome (SS) developed a low-grade mucosa-ass

233 Differences in diagnostic criteria for Sjogren's Syndrome (SS) have led to confusion in the res

234 inflammation accelerates the development of Sjogren's syndrome (SS) in genetically susceptible mice.

235 Sjogren's syndrome (SS) is a chronic autoimmune disease

236 Sjogren's syndrome (SS) is a chronic autoimmune disorder

237 Sjogren's syndrome (SS) is a chronic inflammatory autoim

238 Primary Sjogren's syndrome (SS) is a common chronic autoimmune d

239 Sjogren's Syndrome (SS) is a human autoimmune disease ch

240 Primary Sjogren's syndrome (SS) is a systemic autoimmune disease

241 Sjogren's syndrome (SS) is an autoimmune condition affec

242 Sjogren's syndrome (SS) is an autoimmune disease affecti

243 Sjogren's syndrome (SS) is an autoimmune disease that is

244 hronic inflammation of the ocular surface in Sjogren's syndrome (SS) is associated with a vision-thre

245 Sjogren's syndrome (SS) is characterized by xerophthalmi

246 Patients with Sjogren's syndrome (SS) or systemic lupus erythematosus

247 ogenesis can occur in the salivary glands of Sjogren's syndrome (SS) patients and is associated with

248 Cathepsin S (CTSS) is highly increased in Sjogren's syndrome (SS) patients tears and in tears and

249 ecules are upregulated in salivary glands of Sjogren's syndrome (SS) patients.

250 uropean Cooperative Group (EEC) criteria for Sjogren's Syndrome (SS) should lead to less confusion in

251 Primary Sjogren's syndrome (SS), a chronic autoimmune disorder o

252 Salivary gland inflammation is a hallmark of Sjogren's syndrome (SS), a common autoimmune disease cha

253 toconjunctivitis sicca (non-SS KCS), 32 with Sjogren's Syndrome (SS), and 48 control subjects.

254 (RA), type 1 diabetes mellitus (DM), primary Sjogren's syndrome (SS), and systemic lupus erythematosu

255 6 normal subjects, six subjects with primary Sjogren's syndrome (SS), and three subjects with SS/SLE

256 In Sjogren's Syndrome (SS), inherent glandular defects, aut

257 The mothers had SLE, Sjogren's syndrome (SS), or undifferentiated autoimmune

258 have been reported in patients with primary Sjogren's syndrome (SS), the role of IL-7 in this diseas

259 acrimal and salivary glands, readily induced Sjogren's syndrome (SS)-like KCS in the recipients.

260 e to determine if these intervals recreate a Sjogren's syndrome (SS)-like phenotype.

261 ated in the affected organs of patients with Sjogren's syndrome (SS).

262 lasia occurs in ocular surface diseases like Sjogren's syndrome (SS).

263 her the Th17/IL-23 system is up-regulated in Sjogren's syndrome (SS).

264 duals with clinical manifestations of SLE or Sjogren's syndrome (SS).

265 that may be used in the detection of primary Sjogren's syndrome (SS).

266 hat etanercept is ineffective in controlling Sjogren's syndrome (SS).

267 ese diabetic (NOD)/ShiLtJ, a mouse model for Sjogren's syndrome (SS).

268 pe I diabetes also develops some features of Sjogren's syndrome (SS).

269 thought to be pivotal in the pathogenesis of Sjogren's syndrome (SS).

270 onjunctivitis sicca (non-SS KCS) and 21 with Sjogren's syndrome (SS).

271 tigens recognized by sera from patients with Sjogren's syndrome (SS).

272 nic to NOD, as a potential model for primary Sjogren's syndrome (SS).

273 ch as systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS).

274 ogy and may occur for many reasons including Sjogren's syndrome (SS).

275 ated in the salivary glands of patients with Sjogren's syndrome (SS).

276 acrimal gland (LG) secretion are features of Sjogren's syndrome (SS).

277 he restoration of salivary gland function in Sjogren's syndrome (SS).

278 medical comorbidities (i.e., hypothyroidism, Sjogren's syndrome, systemic lupus erythematosus), parti

279 requently found in the sera of patients with Sjogren's syndrome, systemic lupus erythematosus, and co

280 of autoantibodies in patients suffering from Sjogren's syndrome, systemic lupus erythematosus, and ne

281 targeted by autoantibodies in patients with Sjogren's syndrome, systemic lupus erythematosus, and ne

282 nly associated with each other, particularly Sjogren's syndrome, systemic lupus erythematosus, and sy

283 hildren appear to be more closely related to Sjogren's syndrome than systemic lupus erythematosus.

284 ated with the most common symptom of primary Sjogren's syndrome, the loss of salivary gland function.

285 In Sjogren's syndrome, the role of B-cell depletion has bee

286 nt part in the autoimmune disease process of Sjogren's syndrome; therefore, several therapies aiming

287 alpha-fodrin protein, common autoantigens in Sjogren's syndrome, via extracellular vesicles in an apo

288 A 50-year-old female with Sjogren's syndrome visited our clinic with acute visual

289 ave been observed in APS1 patients including Sjogren's syndrome, vitiligo, alopecia, uveitis, and oth

290 though with this method, an association with Sjogren's syndrome was not identified.

291 d artery occlusion (BCCAO) in a patient with Sjogren's syndrome was not reported before.

292 Twelve female patients with primary Sjogren's syndrome were administered rituximab.

293 Risks of RA, scleroderma, and Sjogren's syndrome were elevated both before and after 1

294 Patients with primary Sjogren's syndrome were enrolled in an open-label trial,

295 No papers specific to Sjogren's syndrome were identified.

296 and spatial analyses of tissues affected by Sjogren's syndrome were undertaken, including the quanti

297 tibodies have been observed in patients with Sjogren's syndrome who are characterised by dryness of b

298 In this report, we describe a female with Sjogren's syndrome who had acute visual loss due to ocul

299 in our understanding of the pathogenesis of Sjogren's syndrome with a focus on the relationship betw

300 y increase UWS flow in patients with primary Sjogren's syndrome, without causing significant adverse